# A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

> **NCT02819271** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 80 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** CXL-1427 Ascending Dose
- **OTHER:** Placebo
- **DRUG:** CXL-1427 Descending Dose

## Key facts

- **NCT ID:** NCT02819271
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02819271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02819271, "A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02819271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*